Near-infrared remote triggering of bio-enzyme activation to control intestinal colonization by orally administered microorganisms
Source abstract
Abstract
Oral biotherapeutics hold significant promise, but their lack of controllability and targeting poses a major challenge, particularly for intestinal bacterial biotherapeutics. In response, we have developed a nanoencapsulation approach that responds to the release of enzyme activity in the organism and activates the enzyme in situ, allowing for controlled colonization of microbes in the gut. The nano-coating comprises a two-layer structure: an inner layer of polydopamine with photothermal and adhesive properties, and an outer layer of gelatin-sodium carboxymethylcellulose, which is hydrolyzed by cellulases in the gut following photothermal interaction with dopamine. We have successfully achieved controlled colonization of a wide range of microorganisms. Furthermore, in a diabetes model, this approach has had a profound impact on regulating glucagon-like peptide-1 (GLP-1) production, β-cell physiology, and promoting insulin secretion. This nanocoating is achieved by in situ activation of cellulase without the need for genetic or targeted molecular modification, representing a new paradigm and alternative strategy for microbial therapy. It not only enables precise and controlled colonization of probiotics but also demonstrates great potential for broader application in the field of oral biotherapy. STATEMENT OF SIGNIFICANCE: We have developed a nano-encapsulation method that triggers enzyme activity in response to enzymatic activity, resulting in the controlled release and adhesion of a wide range of microorganisms in the gut. The nano coating comprises two layers: an inner layer of polydopamine with photothermal and adhesion properties, and an outer layer of a gelatin-sodium carboxymethylcellulose polymer, which can be hydrolyzed by cellulases in the intestine. Additionally, this method allows for the preparation of various microbial coatings. This approach holds significant promise for regulating GLP-1 production, the physiological function of pancreatic β-cells, and promoting insulin secretion in diabetes models.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Gut microbiota and health · Microbial Inactivation Methods · Hydrogen's biological and therapeutic effects
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (37)
Show source-provided references
1. Transkingdom interactions between Lactobacilli and hepatic mitochondria attenuate western diet-induced diabetes10.1038/s41467-020-20313-x ↗
2. An orally delivered microbial cocktail for the removal of nitrogenous metabolic waste in animal models of kidney failure10.1038/s41551-020-0582-1 ↗
3. Microbe-mediated intestinal NOD2 stimulation improves linear growth of undernourished infant mice10.1126/science.ade9767 ↗
4. Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier10.1038/s41579-018-0036-x ↗
5. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease10.1016/j.cell.2016.11.018 ↗
6. Artificial-enzymes-armed Bifidobacterium longum probiotics for alleviating intestinal inflammation and microbiota dysbiosis10.1038/s41565-023-01346-x ↗
7. Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease10.1038/s41591-021-01390-x ↗
8. Microalgae-based oral microcarriers for gut microbiota homeostasis and intestinal protection in cancer radiotherapy10.1038/s41467-022-28744-4 ↗
9. The landscape of mRNA nanomedicine10.1038/s41591-022-02061-1 ↗
10. Biointerfacial self-assembly generates lipid membrane coated bacteria for enhanced oral delivery and treatment10.1038/s41467-019-13727-9 ↗
11. Gut microbiota: a potential new territory for drug targeting10.1038/nrd2505 ↗
12. T2DM treatment trial results10.1038/s41574-019-0234-2 ↗
13. Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery10.1038/nrendo.2016.51 ↗
14. Microbiota in pancreatic health and disease: the next frontier in microbiome research10.1038/s41575-019-0242-7 ↗
15. Magnetically steerable bacterial microrobots moving in 3D biological matrices for stimuli-responsive cargo delivery10.1126/sciadv.abo6163 ↗
16. & Xie, C.Oral polyphenol-armored nanomedicine for targeted modulation of gut microbiota-brain interactions in colitis10.1126/sciadv.adf3887 ↗
17. Bioinspired oral delivery devices10.1038/s44222-022-00006-4 ↗
18. Orally deliverable strategy based on microalgal biomass for intestinal disease treatment10.1126/sciadv.abi9265 ↗
19. Revealing nature's cellulase diversity: the digestion mechanism of Caldicellulosiruptor bescii CelA10.1126/science.1244273 ↗
20. A natural allele of OsMS1 responds to temperature changes and confers thermosensitive genic male sterility10.1038/s41467-022-29648-z ↗
21. A bacterial pioneer produces cellulase complexes that persist through community succession10.1038/s41564-017-0052-z ↗
22. Living microecological hydrogels for wound healing10.1126/sciadv.adg3478 ↗
23. Polydopamine-based nanostructures: a new generation of versatile, multi-tasking, and smart theranostic tools10.1016/j.nantod.2024.102151 ↗
24. Type 2 diabetes and inflammatory bowel disease: a bidirectional two-sample Mendelian randomization study10.1038/s41598-024-55869-x ↗
25. Regulating the absorption spectrum of polydopamine10.1126/sciadv.abb4696 ↗
26. Gut microbiota in human metabolic health and disease10.1038/s41579-020-0433-9 ↗
27. Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease10.1038/s41591-021-01390-x ↗
28. Bioinspired oral delivery devices10.1038/s44222-022-00006-4 ↗
29. The mouse intestinal bacterial collection (miBC) provides host-specific insight into cultured diversity and functional potential of the gut microbiota10.1038/nmicrobiol.2016.131 ↗
30. Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release10.1038/s41586-018-0735-5 ↗
31. Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes10.1038/s41586-022-04754-6 ↗
32. The extracellular surface of the GLP-1 receptor is a molecular trigger for biased agonism10.1016/j.cell.2016.05.023 ↗
33. GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice10.1038/s42255-022-00617-6 ↗
34. Chemogenetics defines receptor-mediated functions of short chain free fatty acids10.1038/s41589-019-0270-1 ↗
35. Functional interactions between the gut microbiota and host metabolism10.1038/nature11552 ↗
36. Microfluidics-derived microparticles with prebiotics and probiotics for enhanced in situ colonization and immunoregulation of colitis10.1021/acs.nanolett.3c03580 ↗
37. The single-cell modification strategies for probiotics delivery in inflammatory bowel disease: a review10.1016/j.carbpol.2023.121472 ↗